Key clinical point: High serum levels of the M2 macrophage marker soluble CD163 could be used as an independent negative prognostic marker in patients with newly diagnosed or relapsed mantle cell lymphoma (MCL).
Major finding: Above-median levels of soluble CD163 (>3000 ng/mL) were significantly associated with shorter progression-free survival (adjusted hazard ratio [aHR] 3.48; P =.006) and overall survival (aHR 4.33; P =.016).
Study details: This study analyzed serum samples from 131 patients with newly diagnosed or relapsed MCL who received immunochemotherapy or targeted treatments (mainly rituximab, ibrutinib, and lenalidomide), respectively.
Disclosures: This study was supported by grants from the Swedish Cancer Society and others. Some authors declared serving as advisory board members or scientific advisors or receiving research funding or honoraria from various organizations.
Source: Nikkarinen A et al. Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma. Blood Adv. 2023 (Jun 30). Doi: 10.1182/bloodadvances.2023010052